These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 10496362)

  • 1. Dose-related nephrotoxicity of carboplatin in children.
    English MW; Skinner R; Pearson AD; Price L; Wyllie R; Craft AW
    Br J Cancer; 1999 Sep; 81(2):336-41. PubMed ID: 10496362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: relevance of age and dose as risk factors.
    Skinner R; Parry A; Price L; Cole M; Craft AW; Pearson AD
    Eur J Cancer; 2009 Dec; 45(18):3213-9. PubMed ID: 19850470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose individualization can minimize nephrotoxicity due to carboplatin therapy in patients with ovarian cancer.
    Donadio C; Lucchesi A; Ardini M; Cosio S; Fanucchi A; Gadducci A
    Ther Drug Monit; 2009 Feb; 31(1):63-9. PubMed ID: 19077927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nephrotoxicity of cisplatin and carboplatin in sarcoma patients: a report from the late effects surveillance system.
    Stöhr W; Paulides M; Bielack S; Jürgens H; Koscielniak E; Rossi R; Langer T; Beck JD
    Pediatr Blood Cancer; 2007 Feb; 48(2):140-7. PubMed ID: 16724313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glomerular toxicity persists 10 years after ifosfamide treatment in childhood and is not predictable by age or dose.
    Skinner R; Parry A; Price L; Cole M; Craft AW; Pearson AD
    Pediatr Blood Cancer; 2010 Jul; 54(7):983-9. PubMed ID: 20405516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors.
    Warren K; Gervais A; Aikin A; Egorin M; Balis FM
    Cancer Chemother Pharmacol; 2004 Sep; 54(3):206-12. PubMed ID: 15156345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flat dosing of carboplatin is justified in adult patients with normal renal function.
    Ekhart C; de Jonge ME; Huitema AD; Schellens JH; Rodenhuis S; Beijnen JH
    Clin Cancer Res; 2006 Nov; 12(21):6502-8. PubMed ID: 17085665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide.
    Hartmann JT; Fels LM; Franzke A; Knop S; Renn M; Maess B; Panagiotou P; Lampe H; Kanz L; Stolte H; Bokemeyer C
    Anticancer Res; 2000; 20(5C):3767-73. PubMed ID: 11268452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of a non cystatin-C-based novel algorithm to calculate individual glomerular filtration rate in cancer patients receiving carboplatin.
    Holweger K; Lipp HP; Beijnen JH; Bokemeyer C; Hartmann JT
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):693-701. PubMed ID: 21136060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal impairment and hypertension in brain tumor patients treated in childhood are mainly associated with cisplatin treatment.
    Pietilä S; Ala-Houhala M; Lenko HL; Harmoinen AP; Turjanmaa V; Mäkipernaa A
    Pediatr Blood Cancer; 2005 Apr; 44(4):363-9. PubMed ID: 15586356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The kidney in children under chemotherapy].
    Cachat F; Guignard JP
    Rev Med Suisse Romande; 1996 Dec; 116(12):985-93. PubMed ID: 9026889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children.
    Loebstein R; Atanackovic G; Bishai R; Wolpin J; Khattak S; Hashemi G; Gobrial M; Baruchel S; Ito S; Koren G
    J Clin Pharmacol; 1999 May; 39(5):454-61. PubMed ID: 10234592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group.
    Skinner R; Cotterill SJ; Stevens MC
    Br J Cancer; 2000 May; 82(10):1636-45. PubMed ID: 10817497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adaptive dosing and platinum-DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours.
    Veal GJ; Errington J; Tilby MJ; Pearson AD; Foot AB; McDowell H; Ellershaw C; Pizer B; Nowell GM; Pearson DG; Boddy AV;
    Br J Cancer; 2007 Mar; 96(5):725-31. PubMed ID: 17299395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the Modified Diet in Renal Disease equation for calculation of carboplatin dose.
    Shord SS; Bressler LR; Radhakrishnan L; Chen N; Villano JL
    Ann Pharmacother; 2009 Feb; 43(2):235-41. PubMed ID: 19193580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose carboplatin and regimen-related toxicity following autologous bone marrow transplant.
    Colby C; Koziol S; McAfee SL; Yeap B; Spitzer TR
    Bone Marrow Transplant; 2002 Mar; 29(6):467-72. PubMed ID: 11960264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacokinetics and individual dose adjustment of carboplatin].
    Chatelut E; Canal P; Bugat R
    Bull Cancer; 2000 Aug; 87 Spec No():17-23. PubMed ID: 11082718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term renal and hearing toxicity of carboplatin in infants treated for localized and unresectable neuroblastoma: results of the SFOP NBL90 study.
    Bergeron C; Dubourg L; Chastagner P; Mechinaud F; Plouvier E; Desfachelles AS; Dusol F; Pautard B; Edan C; Plantaz D; Froehlich P; Rubie H
    Pediatr Blood Cancer; 2005 Jul; 45(1):32-6. PubMed ID: 15768383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of predictive formulae for glomerular filtration rate for carboplatin dosing in gynecological malignancies.
    de Lemos ML; Hsieh T; Hamata L; Levin A; Swenerton K; Djurdjev O; Vu T; Hu F; Conklin J; Malfair Taylor SC
    Gynecol Oncol; 2006 Dec; 103(3):1063-9. PubMed ID: 16875719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-center study of two dose levels of paclitaxel with carboplatin in locally advanced and metastatic non-small cell lung cancer (NSCLC).
    Glorieux P; Ortmanns P; Marien S; Degives R; Degraeve D; Potvin M; Grauwels D; Schallier D
    Anticancer Res; 2001; 21(2B):1487-94. PubMed ID: 11396237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.